Journal
CELL STEM CELL
Volume 21, Issue 2, Pages 256-+Publisher
CELL PRESS
DOI: 10.1016/j.stem.2017.06.016
Keywords
-
Categories
Funding
- National Institutes of Health [R01-AR063630, R01OD023700]
- Research Scholar Grant from the American Cancer Society [RSG-13-198-01]
- V scholar award from V foundation
- National Institute of Health [DK-020595]
Ask authors/readers for more resources
Somatic gene therapy is a promising approach for treating otherwise terminal or debilitating diseases. The human skin is a promising conduit for genetic engineering, as it is the largest and most accessible organ, epidermal autografts and tissue-engineered skin equivalents have been successfully deployed in clinical applications, and skin epidermal stem/progenitor cells for generating such grafts are easy to obtain and expand in vitro. Here, we develop skin grafts from mouse and human epidermal progenitors that were engineered by CRISPR-mediated genome editing to controllably release GLP-1 (glucagon-like peptide 1), a critical incretin that regulates blood glucose homeostasis. GLP-1 induction from engineered mouse cells grafted onto immunocompetent hosts increased insulin secretion and reversed high-fat-diet-induced weight gain and insulin resistance. Taken together, these results highlight the clinical potential of developing long-lasting, safe, and versatile gene therapy approaches based on engineering epidermal progenitor cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available